ejpmr, 2025, 12(4), 126-138

SJIF Impact Factor 7.065

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

A REVIEW ON CLINICAL DRUG DVELOPMENT PATHWAYS

Ishita[1], Asha Devi[2]*, Muskan Sharma[2], Priyanka Kaundal[2]

[1]Student at School of Pharmacy & Emerging Sciences, Baddi University of Emerging Sciences & Technology, Makhnumajra, Distt. Solan (H.P.) – 173205.

[2]Faculty at School of Pharmacy & Emerging Sciences, Baddi University of Emerging Sciences & Technology, Makhnumajra, Distt. Solan (H.P.) – 173205

***Corresponding Author: Asha Devi**

Assistant Professor (Pharmacology) School of Pharmacy & Emerging Sciences Baddi University of Emerging Sciences & Technology Makhnumajra, Distt. Solan (H.P.) – 173205. Email Id: asha.devi@baddiuniv.ac.in

Article Received on 13/02/2025 **Article Revised on 05/03/2025** **Article Accepted on 26/03/2025**

ABSTRACT

Effective trial management is necessary to oversee clinical trials of any size and complexity, and during the past three decades, trialists have created and improved the trial management wheel. We propose that it is time to create standard trial management principles and build strong protocols to enhance the timely and successful implementation of significant clinical studies for patient benefit techniques for assessment. This outlines the steps and processes required in organizing, carrying out, and disclosing monitoring activities for extensive clinical trials of pharmaceutical and experimental items, with an emphasis on those carried out in environments with limited resources. Any clinical study must include clinical trial monitoring to guarantee protocol compliance, data quality, and subject safety. In recent years, regulatory bodies and industry professionals such as a risk-based strategy to clinical trials has been promoted by the USFDA and ICH. Clinical trial monitoring and auditing is a complicated procedure, and using traditional auditing techniques raises the cost of clinical studies. This procedure outlines methods for clinical trial cost-effective monitoring. By examining all issues and expenses, sampling techniques for source documentation can be utilized to reduce costs without compromising quality. Clinical research activities and documentation are subjected to an independent, methodical assessment to ascertain whether the procedures involved in starting and overseeing this clinical research were carried out and whether the data was gathered, examined, and reported in accordance with standard operating procedures with the protocol. System audits ought to be controllable and reasonably sized given the available resources (may be handled). Audits must be planned and carried out to produce outcomes that are acceptable. Above all, avoid downgrading your audit program and leave time for audits that aren't scheduled.

KEYWORDS: Manage, Monitor, Audit, Clinical Trial, Quality Evaluate.

1. INTRODUCTION

Drug development is a costly, time-consuming, high-risk industry that takes ten to fifteen years and has a high attrition rate. It is motivated by the likelihood of success, disease prevalence, and medical necessity. The identification of drug candidates is an iterative process that involves chemistry and biology, honing the molecular characteristics until a substance that can be developed for human use is discovered. Generally speaking, only one out of every thousand synthesized molecules is chosen to advance to the clinic. A wide range of in vitro and in vivo test methods are used to determine the drug's pharmacology and biochemistry before it is administered to humans. Additionally, it is required by law that the medication be given to animals in order to evaluate its safety. Animal testing at a later stage is also necessary to evaluate carcinogenicity and reproductive system impacts.[1]

Phase I of clinical drug development involves evaluating pharmacokinetics, safety, and toleration mostly in healthy volunteers; phase II involves establishing efficacy and a dose- response relationship in a cohort of patients with the target disease; and large-scale phase III studies confirm effectiveness and safety. Only around 10% of medications that begin the trial phase will reach the market, according to experience. Before a medicine is approved by regulatory bodies, it must prove to be safe and effective in the target patient group and its advantages must exceed its disadvantages. The production of pharmaceutical goods and the conduct of pre-clinical and clinical studies are subject to stringent regulatory criteria. Through post-marketing monitoring of adverse events, the safety of the new medication is evaluated after it has been approved.[1]

The business of developing drugs is dangerous. Choosing one or two compounds for development from

the large pool of options provided by the engines of high-throughput discovery frequently determines success or failure. A promising candidate must have sufficient bioactivity, suitable physical chemical characteristics that allow for formulation development, the capacity to pass across important membranes, a tolerable level of metabolic stability, and suitable human safety and effectiveness. A series of advanced in vitro studies that supplement conventional in vivo animal safety evaluations are necessary to forecast a drug's behaviour in humans prior to clinical testing. This review addresses how to strategically determine which non-clinical investigations ought to be carried out in order to give stakeholders in clinical drug trials the necessary comfort and direction.[2]

2. PHASES OF DRUG DEVELOPMENT PROCESS

2.1 Preclinical Trials
2.2 Clinical Trials

2.1 PRECLINICAL TRIALS

Prior to human testing, preclinical research attempts to provide details regarding the safety and effectiveness of a medication candidate. Additionally, they often comprise both in vitro and in vivo experiments and might offer proof of the compound's biological action. Preclinical research must abide by the rules set forth by Good Laboratory Practice to guarantee accurate results, which are necessary before submitting an IND for clearance by agencies like the FDA. Research on pharmacokinetics, pharmacodynamics, and toxicology give important information about the compound's dosage and toxicity levels, which are necessary to assess if it is appropriate and relatively safe to move forward with clinical research.[3]

Appropriate preclinical models that are as similar to the target population as possible are necessary to produce pertinent results from preclinical investigations with a high degree of generalizability. This usually entails a number of tests utilizing in vivo, in vitro, and more recently, in silico models.[4]

In vitro models – studying the drug in a petri dish

One rather quick, easy, and economical method of preclinical testing is in vitro research. These investigations use tissue, organ, and cell cultures, or they concentrate on specific cell constituents such proteins or other biological macromolecules. Studies conducted in vitro allow for strict control and observation. Of experimental conditions and frequently offer mechanistic proof of the method of action of the drug under inquiry. The fact that isolated cells might not respond in a petri dish the same way they would in the body, where they interact and converse with millions of other cells, limits the potential for mechanistic insights that in vitro models might offer. Therefore, before moving into a clinical setting, more advanced preclinical models are needed to determine the safety profile of the experimental chemical.[3]

In vivo models – is the mouse the best experimental animal?

Based on a variety of animal models, in vivo investigations take into account the entire body. Like human research, animal experimentation is strictly controlled in the majority of nations, and local ethical review committees must grant approval to guarantee that no needless harm is done to the subjects of experiments. Recent developments in telemetric monitoring, micro sampling, and non-invasive imaging technologies have improved the use of animal models in drug research.[3]

Controlling experimental conditions for in vivo research is obviously much more difficult, and because living organisms are complex, chemicals may behave differently from what is predicted from test-tube results. The selection of suitable animal models depends on a wide range of factors and necessitates knowledge of metabolic pathways, species-specific physiology, and similarities with the target organ, in addition to economical, legal, and ethical considerations. To meet FDA regulations, in vivo studies are usually conducted in a rodent (such as a mouse, guinea pig, or hamster) and non-rodent (such as a rabbit, dog, pig, etc.) model. Primate testing (e.g., monkeys, apes, etc.) is done seldom and usually for bigger compounds, whereas mice, rats, and dogs are among the most commonly employed animal models. The mouse is one of the most widely used animal models in pharmacological testing. Human and mouse genomes are quite similar; 99 percent of all mouse genes are shared with human genes. Furthermore, it is now quite easy to manipulate the genome of this organism. However, species-specific variations in drug metabolism, host immunological response, and treatment results are impacted by tumour heterogeneity. Since species-specific variations in pharmacokinetics and pharmacodynamics are also significant, mouse models frequently have low predictive power for therapeutic efficacy.[4]

However, mouse models are the gold standard for testing medications that target cancer because there aren't any better options. Historically, the only way to create such mouse cancer models was to transfer cultured human tumour cells (cell lines) into immunocompromised mice, like naked or severely mice with a combined immunodeficiency (SCID). 12 Xenografting is the transplantation of cells, tissue, or organs from one species to another. Cancer cells are injected subcutaneously in these cells line-derived xenograft (CDX) models, and tumour growth curves are created by periodically evaluating the tumour’s size. When a medication candidate is administered to tumour-bearing mice, data about its capacity to slow tumour growth and, consequently, its in vivo efficacy are obtained. Nevertheless, the artificial circumstances used to passage these cell lines do not replicate the natural tumour microenvironment. As a result, human disease may not be identical to CDX models.[4]

2.2 CLINICAL TRIALS

A clinical trial is a comprehensive study conducted on human participants to assess the efficacy and safety of any novel medication. Clinical trials are studies used in medical research and development that determine the safety and effectiveness of treatments for human health. Clinical trials are carried out only after the nation where permission of the dang is sought has granted it and after adequate information regarding the non-clinical safety and health authority/ethics committee quality has been obtained. The primary method for introducing new medications to the market is clinical trials.[5]

Protecting trial participants' rights and safety as well as lowering the possibility that bias would skew trial results—thereby jeopardizing future patient safety—should be the primary goals of quality assurance techniques used in randomized trials. Trial monitoring is a wide term that encompasses oversight techniques that start with the study's design and persist until it is documented in a publication, contributes to the accomplishment of these objectives. Based on talks at the Sensible Guidelines workshop in January 2007 in Washington, D.C., this study aims to provide a new perspective on how various forms of monitoring can enhance the quality of conclusions drawn from randomized trial data. First, we look at the many kinds of errors that can occur in randomized trials and the situations in which they could add bias or have a negative impact on trial participant safety. Second, we go over the many kinds of monitoring that are available and how well they work to find the kinds of problems that we have identified. Third, we offer recommendations on how the risk assessment of each specific trial can be utilized to determine the probability of those errors, which will help direct the creation of a suitable trial monitoring plan. Lastly, we look at areas where more research could enhance study monitoring techniques.[5]

Numerous clinical trials examine the length of survival for cancer patients who are randomly assigned to various therapies. The surprising result of extensive research into potential methods of interpreting the data from such trials is the finding that two methods—life table graphs and log rank P-values—that are so straightforward that non-statisticians can easily learn them are frequently more sensitive and accurate than any of the complex alternatives that have been taken into consideration. These two methods are sufficiently explained in Part II of this study, which will be published in the upcoming issue, to be carried out completely without statistical assistance. This issue's Part I teaches statistical concepts such as patient numbers, withdrawals, stratification, and so forth without the need for technical statistical terminology. Even common statistical concepts like chi-square (in Part II) and random number tables are provided and explained so that no further papers or tables need to be consulted.[6]

2.2.1 Clinical Phases

2.2.1.1 Phase

Phase 0 has been considered a recent addition to the trial's exploration. Initially, the human trials were conducted in compliance with the 2006 guidance on exploratory investigational new drug (IND) research issued by the US Food and Drug Administration (FDA). Microdose studies, another name for phase 0 trials, are created with the intention of creation of a promising medication with the particular qualities anticipated from preclinical research. Additionally, Phase 0's unique features include giving a single subtherapeutic dose of the study medicine to a limited number of volunteers or patients (10–150) in order to gather initial data on the drug's pharmacokinetic and pharmacodynamic properties. Surprisingly, Phase 0 studies do not provide any specific data about the safety and efficacy of the test drug. Furthermore, the drug development companies have been noted to perform Phase 0 studies for ranking the drug candidate in order to decide the pharmacokinetic parameters on humans for further development.[5]

2.2.1.2 Phase I

Phase I trials, which include the initial round of volunteer testing, are the third stage of successful clinical trials. Only 20 to 100 people are chosen for the investigation in this experiment. This stage is typically carried out to examine a drug's pharmacodynamic, pharmacokinetic, tolerance, and safety characteristics. These studies are frequently conducted in healthcare facilities with full-time staff members keeping an eye on the participants1. Additionally, the commercial contract research organizations (CROs) who conduct these clinical trials on behalf of researchers or pharmaceutical firms frequently administer the clinics for these studies. In order to identify the safest and optimal dose, Phase I trials, also known as dose magnifying studies, include the usual range of doses. In Phase I trials, healthy subjects are typically chosen. The Phase I trials include the standard range of dosage and be also known as dose magnifying studies, which are used to identify the safest and most effective dosage. In Phase I trials, healthy subjects are typically chosen. The volunteers in this research receive round-the-clock medical care and are monitored by full- time clinical professionals in controlled settings known as CPUS (central pharmacological units).[7]

Additionally, the Phase 1 trials are divided into two types: multiple ascending dose (MAD) trials and single ascending dose (SAD) trials. A limited number of volunteers are chosen for SAD, given a single dosage of the medication, and monitored for a specific amount of time. Additionally, the drug's dosage is raised and given to a fresh group of volunteers if no side effects have been observed and safe pharmacokinetic data has been produced. If the drug is detected the number of participants increases if there is intolerable toxicity or negative impact on them. Furthermore, the higher dose is

stopped and the previous dose is designated as the maximum tolerated dose (MTD) if any intolerable toxicity is detected. When a third of the volunteers encounter intolerable toxicity, such designs take MTD into account. The purpose of the investigations in MAD is to comprehend the pharmacokinetic and pharmacodynamic characteristics of the test substance at multiple doses.[8]

2.2.1.3 Phase II

The dose calculation of the test medicine has already been completed in Phase I studies, as previously stated. Analysing if the medication has a biological and therapeutic level is the next goal 4-5. The studies have been carried out in large groups in Phase II trials. (100–300) and are intended to examine how the medication functions in conjunction with the Phase 1 safety assessment in the larger participants. If there is sufficient evidence of metabolic rate variation, genetic testing is widely used. The Phase II trials are separated into two categories: Phase IIb trials, which are intended to assess the efficacy of the treatment, and Phase II a clinical trial, which are rarely intended to assess the dose need. Additionally, several studies have been conducted using a combination approach to test for both toxicity and efficacy. Phase II trials are conducted in specialized clinical facilities, such as those found in universities and medical facilities). Phase II trials are where the innovative medications are tested because of the wide spectrum of toxicity that can be found there.[9]

2.2.1.4 Phase III

It has been proposed that phase III clinical trials be created to examine a new drug's effectiveness and therapeutic impact in clinical settings. Randomized phase III trials involving 300–3000 participants or more have been carried out with the goal of attain a definitive evaluation of the novel medication by contrasting it with the conventional pharmacological treatment. Additionally, the Phase III studies have been regarded as the most costly, time- consuming, and challenging to plan and conduct because of their larger scale and longer duration. Chronic diseases that have an evaluation period corresponding to the intervention period can be employed in phase III trials. Following Phase III trials, when drug satisfaction has been attained, the report is compiled with a thorough explanation of the manufacturing process, its results, formulation details, and half-life. Additionally, the data gathered are submitted to the "regulatory submission" in the hopes that the sponsor will receive approval to market the medication. Additionally, the particular medication is removed from the market right once if any negative side effects have been documented anywhere.[10]

2.2.1.5 Phase IV

Phase IV, often known as "post marketing surveillance" (pharmacovigilance), covers the technical support of the medication following the acquisition of a sale authorization. The sponsoring corporation or a regulatory body may assist in conducting the Phase IV research for discovering a new medication market. These trials are intended to determine whether any long-term negative effects have been observed over a much larger patient population over a longer time period, which was not feasible during Phase II and Phase III trials. However, the entire medication development process from the lab to this stage takes between 12 to 18 years.[11]

CLINICAL DRUG DEVELOPMENT PHASE DECISION



Fig.1: Drug Development Phases.[5]

3. Monitoring & Clinical Monitoring

3.1 Monitoring

Monitoring a clinical trial's progress and making sure it is carried out, documented, and reported in compliance with the protocol, SOPs, GCPs, and any applicable regulatory requirements. The selection of the type and scope of monitoring should be predicated on factors like the goal, intent, design, intricacy, blinding, scale, and trial outcomes. On-site monitoring is generally required prior to, during, and following the study. A formal guideline exists that can guarantee proper trial conduct in compliance with GCP. Sponsors designate monitors. The goal is to ensure that human subjects' rights and welfare are upheld. According to the source documents, the reported trial data are correct, comprehensive, and verified. the experiment being conducted according to protocol. GCPs and any related legal requirements.[12]

3.1.1 Management

The supervision and planning necessary to carry out a clinical trial are referred to as clinical trial management. From the initial idea to the final analysis and reporting, CTM is in charge of all facets of clinical research investigations. It aims to maximize trial efficiency, preserve regulatory compliance, safeguard patient safety, and assure trial success. It is vital to guarantee that experiments yield results that solve patient safety issues and further medical research.[12]

3.1.2 Feature

- Trials for collaborative audits and traceability.
- A rise in operational effectiveness.

3.1.3 Auditing

The verification of financial accounts utilized in clinical trials has long been referred to as an audit. As a someone outside the system, the auditor's job is to attest to the veracity of the data in reports. That is, that it has been produced, gathered, and purchased in compliance with the regulations. An audit conducted by a sponsor aims to assess the trial's compliance with.

- Quality systems & SOPS.
- Protocol.
- Good clinical practices and other relevant regulatory requirements.
- Auditors are not involved in the handling of clinical trial data.
- Sponsor or site.[12] [13]

3.2 CLINICAL MONITORING

A vital component of medical research and treatment is clinical monitoring. It entails monitoring the development of clinical trials or patient therapies to guarantee protocol adherence, safety, and effectiveness. Monitoring in clinical trials include tasks including data verification, accuracy, evaluating patient safety, and verifying that the experiment is carried out in accordance with legal and ethical criteria. This may entail speaking with study participants and medical professionals, visiting the location, and going over medical records. Reliable trial findings, patient welfare, and the integrity of research data are all protected by efficient clinical monitoring. It is crucial to the general success of clinical trials as well as the creation of novel therapies and therapists.[14]



Fig.2 Objectives of monitoring.[15]

3.2.1 Monitoring Clinical Research, which includes a variety of tasks to ensure the accuracy and safety of data gathered, is essential to the success of clinical studies. Clinical trial procedures must be carried out in accordance with legal requirements, give human research participants' safety top priority, and reduce any possible health hazards. Monitoring tasks include data assessment and study site audits, precision and thoroughness, process, and scrutiny of amendments.[16]

Steps to Monitoring Clinical Research

1. **Craft a Robust Monitoring Strategy:** Create a comprehensive monitoring plan that includes all necessary components. This entails defining the kinds of monitoring tasks, determining how frequently monitoring visits will occur, and detailing techniques for gathering data and defining precise standards for acceptable performance.[17]
2. **Conducting Monitors Visits:** Conduct periodic monitoring visits (PMV), initiation visits (IVs), and COVs in accordance with regulatory requirements and the complexity of the experiment. Maintain sound clinical practices during each productive visit practice standards by carefully going over the data collecting tools and source materials. Examine patient enrolment records for accuracy, making note of any inconsistencies in the detailed visit report.[16]
3. **Reporting Findings:** Give investigators

constructive criticism that emphasizes their work. When necessary, recommend training or instructional programs to resolve any noncompliance with protocol rules or regulations. Make sure the necessary paperwork is completed prior to closing a particular research location.[16]

4. **Ensuring Quality Assurance:** Verify the precision of the tracking devices that monitors use while on duty. Throughout the monitoring process, evaluate the risks associated with the shortcomings that have been found. Perform routine internal audits and evaluations to ensure adherence to established SOPs and recommendations concerning clinical research monitoring operations. Improve internal quality system procedures by putting preventive measures into place based on audit and evaluation results.[17]

4. Types of monitoring



Fig.3 Types of Clinical Monitoring.[18] [19]

4.1 The purposes of clinical trial monitoring

- Human participants' rights and welfare are safeguarded.
- According to source documentation (records of clinical findings, observations, or other activities in a clinical trial), the presented trial data are accurate, comprehensive, and verifiable.
- The trial is being conducted in accordance with the necessary regulatory requirements, GCP, and the protocol.
- Defend the participants' rights, security, and welfare.
- Make that the trial is carried out in compliance with the authorized procedure.
- Serve as a point of contact for the sponsor, research sites, and other interested parties.
- Conform the sponsor of the trial's developments and difficulties.
- Respond quickly to questions and concerns about the site.
- When necessary, carry out corrective and preventative actions (CAPA).
- Inform the sponsor of the trial's status and difficulties.
- Make that research medications or equipment are appropriately administered, stored, and tracked.
- Track the hiring process and make sure scheduled deadlines are met.
- Verify the data in the case report files (CRFs) for correctness, completeness, and consistency with the original documents.
- Make sure that all trial-related actions are properly documented.
- Identify and stop data manipulation or fraud.[20]

4.2 Selection, Qualification of Monitoring

- The sponsor selects the monitors.
- Training ought to be appropriate.
- Possess clinical and scientific expertise.
- Clinical research experience, with an emphasis on clinical trial monitoring.
- Knowledge of treatment areas, protocols, and trial stages I–IV.

- Knowledge of regulatory regulations, such as those set forth by the FDA, EMA, or ICH-GCP.
- Proficiency with clinical trial management systems (CTMS) and electronic data capture (EDC) systems.
- Excellent reporting and data analysis abilities to spot patterns and address inconsistencies.
- Familiarity with trial-specific tools and protocols.
- Check the applicant's credentials, experience, and certifications.
- Examine their knowledge of the therapeutic domains that are pertinent to the research.
- Track performance using data quality evaluation, sponsors' and site employees' input.
- To guarantee compliance with trial requirements, do evaluations on a regular basis.
- Make sure you are knowledgeable about the clinical trials' indication or therapeutic area.
- Assess your understanding of particular patient populations, experimental products, and study endpoints.[21]



Fig. 4: Monitors Responsibilities.[20]

4.3 MONITORING REPORT

Following every visit and other trial-related correspondence, the monitor sends the sponsor a written report in accordance with the sponsor's SOPs.

- Submitted to sponsor
- Reports should include:

1. Date
2. Site
3. Name of monitor.
4. The name of the researcher or other people who were contacted for the study.
5. Overview of the monitor inspection, flaws, and deviations.
6. It includes the conclusions and the next steps.[22]

5. MONITORING RESOURCE

5.1 National Institutes of Health (NIH): Clinical Research Monitoring

Information about NIH's guidelines for clinical research monitoring can be found at this link. These standards cover subjects including investigator roles and responsibilities, data safety monitoring boards, and procedures for reporting unforeseen issues and adverse events.[23]

5.2 National Institutes of Health (NIH): Guide to Clinical Research Monitoring

This thorough manual takes readers through every facet of clinical research monitoring, including subjects like study design, randomization techniques, data management, regulatory compliance requirements, monitoring plans and reports, and quality safety evaluations and improvement projects FDA: Guidelines for the Monitoring of Clinical Trials in the United States.[22]

5.3 US Food and Drug Administration (FDA): Guidelines for Clinical Trials Monitoring

This FDA document highlights the significance of efficient monitoring in clinical trials, gives a summary of the many responsibilities in a clinical trial, and goes into depth about the necessary components for putting an efficient monitoring system into place tactics like recording unfavourable events and risk evaluations.[23]

Clinical studies benefit greatly from efficient monitoring, which should be incorporated from the very beginning of trial design. It might be difficult to run clinical trials in settings with limited resources, but meticulous preparation and efficient, well-executed monitoring can help to ensure accurate and dependable scientific results while following national and international regulations and preserving patient safety at all times.[23]

6. Managing Clinical Trials

Clinical trial management is organizing several trial

components to guarantee a successful outcome. This include designing the experiment, finding volunteers, getting regulatory approvals, putting procedures in place, keeping an eye on data gathering, and evaluating the outcomes. It includes managing every step of a clinical trial's execution, from the preliminary planning phases to the last data analysis as well as reporting. Maintaining the integrity of the study, guaranteeing participant safety, and producing trustworthy results that progress healthcare all depend on the efficient administration of clinical trials.[24]

According to Farrell and Kenyan in The Guide to Efficient Trial Management, active management of every trial component is essential for success, based on their experience with non-commercial academic-initiated trials. In order for physicians to find participants, they ought to be taught in trial procedures and feel at ease. Numerous techniques, including one- on-one instruction, group projects, and distant learning techniques (online videos and teleconferences), can be used to accomplish this. The trial team must plan national and worldwide presentations and debates to consistently emphasize the significance of the trial. For a trial manager and the trial team, keeping a personal connection with a collaborative group of clinicians—whether there are seven or seven hundred—is perhaps the most difficult task, but one that will make the trial more coherent.[25]

A project management plan must contain information on how to develop and oversee every facet of a trial, including providing support to the steering committee and the independent data monitoring committee. Of utmost importance, however, is how the trial's daily operations will be organized and run. A key component of this strategy is the creation of a solid statistical analysis plan backed by enough time and resources to effectively complete the experiment.[26]



Fig. 5: Managing Clinical Trials.[25]

7. STAGES OF MANAGING CLINICAL TRIAL

STAGES OF MANAGING IN CLINICAL TRIALS	
INITIATION	• Develop protocol • Approval protocol
PLAN	• Select site • Initiate site • Recruit site
EXECUTE	☐Conduct study
MONITORs CONTROL	• Site management • Quality management • Supply management
CLOSEOUT	• Analysis • Database lock • Write report ☐Archival

8. STEPS OF MAINTAINING OF CLINICAL TRIALS

1. A Trial Manager
2. Project Planning
3. Little effort on the part of participants and investigators
4. Communication
5. Education, Training and Experience

8.1 A TRIAL MANAGER

A competent trial manager who is involved in the funding application and trial design will contribute significantly to the trial's practicality, possibly preventing unworkable systems and saving money. The primary

duties of a trial coordinator as follows.

- Playing a key part in organizing, directing, and finishing a project.
- Outstanding presenting and communication abilities.
- The capacity to coordinate and inspire others.[27]

8.2 Project PLANNING

Many characteristics of a clinical trial are similar to those of any other kind of commercial project as described by project management. Among these characteristics are the following.

- Requiring a team
- A set time scale
- Outlined resources to accomplish its goal
- Activities that must be finished

Every project is made up of a number of steps that must be taken in order to get outcomes. The five fundamental steps of the procedure are.

a) Initiating
b) Planning
c) Executing
d) Monitoring and Control
e) Analysis and reporting

A trial's life cycle is reflected in these five phases. Thus, the secret to successful trial management is creating a management strategy. A project management strategy must contain information about how to develop and oversee every facet of a trial, including supporting both the independent data monitoring committee and the steering committee. Along with outlining who will be in charge of crucial tasks like hiring and managing staff, communicating with the collaborative group, monitoring recruitment, managing data, and promoting the project, the project plan should also outline who will be in charge of safety reporting, analysis, report writing, and sharing trial results. The project plan should outline the goals of the trialists, the allocation of resources, and the timeline.[27]

8.3 Minimal work for investigators and participant

Making sure recruitment processes run smoothly alongside regular procedures ensures that investigators and participants have less work to do. To ensure that recruiting for the trial becomes a daily occurrence, site visits and conversations with personnel at the location where recruitment takes place are necessary. The hiring process must be reasonable and useful. For instance, web randomization would not be feasible for an emergency experiment or a trial taking place in an intensive care unit. The recruitment team should have easy access to the information required to address the clinical question. Early on in the trial planning process, the data collection forms should be developed. Dummy tables that represent the final analysis are ideal would be created as part of the plan for statistical analysis to make sure that no extraneous data is collected by the data collection forms.[28]

8.4 Communication

A trial's communication strategy must focus on giving investigators frequent feedback that makes them feel involved because they need to feel appreciated and like they are a part of an inclusive team that is addressing a significant clinical question. Keeping in mind the target demographic and customizing everything maintaining the trial investigator's preferred communication medium (phone, email, letter, website, and physical contact) will help busy doctors prioritize their tasks and make sure they feel that the communication is personal.[28]

8.5 Education, Training, and Experience

Each member of a trial team should be qualified to carry out their duties based on their education, experience, and training. Due to the lack of specialist trial management training, it is challenging for trial managers to adhere to this rule. A trial manager's education in the field cannot be verified by any recognized qualification. Courses on the practical management of clinical trials are necessary, according to a 2005 UKTMN study. Sixty percent of the 284 trial managers polled said they preferred flexibility, accessibility, and specificity over higher education credentials.[27]

9. AUDITING CLINICAL TRIALS

Clinical trial auditing is examining and assessing the study's conduct to make sure that procedures, laws, and quality standards are being followed. It seeks to confirm the dependability and correctness of the information gathered throughout the trial. Audits can be carried out by impartial auditors or regulatory bodies to evaluate the trial's compliance with Good Clinical Practice (GCP) standards, data collection procedures, documentation standards, and participant consent, among other elements. Potential problems or inconsistencies can be found and fixed by auditing clinical trials, preserving the validity and integrity of the study.[29]

9.1 Objective of Audit

The audit's form is determined by the auditor's mission because it is meant to confirm what has occurred. Random sampling, a methodical evaluation of the investigators' work, or, in the event of suspected fraud, the service provider can all be used to carry out the audit on-site in charge of the trial. It is also possible to audit labs that perform supplementary or biological tests. As a result, the options are numerous and must inevitably be restricted. System audits are typically conducted on a regular basis to evaluate the overall state of affairs without specifically mentioning clinical trials. On-site audits, on the other hand, are specifically carried out to increase the trial's credibility and, consequently, its acceptability by the state supervisory bodies. They are directly related to clinical trials.[29]

9.2 Purpose of Audit

A sponsor's audit's objective is to assess the trial's conduct and adherence to.

- Quality System and SOPs

- Protocol
- Appropriate clinical procedures and additional relevant legal requirements

9.3 Principle of Audit

- It's all about enhancing patient care.
- Ought to be considered a regular practice.
- Gaining a critical perspective on our actions.
- Making constant efforts to make things better

9.4 How to execute an audit

- Before the audit
- During the audit
- After the audit

BEFORE THE AUDIT PROCESS

- The auditor gets in touch with the location to set up a time and date that works for both parties to conduct the audit.
- The CRC is notified of the audit's comprehensive schedule as well as the documents that will be examined.
- To be aware of the trial, the auditor analyses the protocol, CRF, local laws and regulations, project-specific guidelines, and pertinent SOPs.[30]

DURING THE AUDIT PROCESS

- Opening meeting.
- An initial meeting between the site crew and the auditor.
- The audit's scope and protocols are briefed by the auditor.
- A chance for the investigator and other trial team members to speak with the auditor.
- Examining papers and gathering data.
- Audit findings.[30]

AFTER THE AUDIT PROCESS

- Within 28 days following the last audit activity, the auditor should release the audit report, which is a private and internal document.
- He informs clinical research staff of the findings that are pertinent to their work, which are categorized as major, minor, and critical.
- The report should be accompanied by a list of preventative and corrective actions.
- Once the corrective actions have been implemented, the trial team should compile and submit a formal audit response to the affected persons.
- An audit certificate attesting to the audit's completion and filing in the clinical trial reports is issued by the auditor once the audit receives satisfactory responses.[30]

10. THE AUDIT CYCLE



Fig: 6 Audit design cycle.[31]

An essential component of GCP is a sponsor's audit of a clinical trial, which is distinct from and independent of monitoring and quality control duties. Its goal is to assess how well the protocol, SOPs, GCP, and relevant regulations are being followed during the study prerequisites.

The sponsor should select the following auditor to conduct a clinical trial audit.

- Regardless of the system or clinical trials.
- Qualified to carry out the audits correctly based on training and experience, and these credentials must to be recorded.[31]

For a trial audit, the sponsor's audit plan and protocols ought to be directed by.

- The trial's significance for submission to regulatory bodies
- The quantity of trial participants
- The trial's nature and intricacy
- The degree of danger to the test participant
- Any issues found.[31]

10.1 Purpose of Clinical Trial Audit

The purpose of a clinical trial audit is to make sure.

- Safeguarding participants in clinical.
- Boost the assurance that the information gathered and then provided is accurate.
- Check for adherence to rules, including those pertaining to Good Clinical Practices (GCPs).[32]

10.2 The most cited clinical trial areas during audit

The most often reported non-compliance areas during clinical trial audits are as follows.

- Procedure for Informed Consent and Documentation.
- A precise and comprehensive study log.
- Verification and documentation of the fulfilment of eligibility requirements.
- Review and reporting of adverse events.
- Study closure or a delay in approvals while research-related activities continue.
- Device/Drug Accountability.
- Protocol adherence.[32]

11. STAGES OF CLINICAL AUDITS

Step 1: Determine the issue or problem

- This step entails choosing a subject or problem to be examined, and it probably entails assessing compliance with medical procedures that have been demonstrated to yield optimal results for patients.[33]

Step 2: Establish norms and criteria

- A criterion is a quantifiable result of treatment, a feature of practice, or a capability. "Parents/caregivers are involved in negotiating or planning their child's care," for instance.
- For every criterion, a standard is the expected level of conformity.[33]

Step 3: Gathering data

- Specifics of what needs to be audited must be determined from the data in order to guarantee that the information gathered is accurate and that only pertinent data is gathered beginning.[33]

Step 4: Evaluate performance in relation to criteria and norms

- This is the stage of analysis, where criteria and standards are used to compare the data collecting results. The final round of study is determining how well the standards were fulfilled and, if relevant, providing justifications for instances in which the standards weren't fulfilled. These justifications might be accepted, meaning they could be included in future standard exception criteria or serve as a focal point for reform initiatives.[34]

Step 5: Putting the change into action

- Following the publication and discussion of the audit's findings, a consensus regarding the suggested modifications must be obtained. Making use of an action plan to it is best practice to document these suggestions; this should indicate who has committed to what and by when. Every point must be clearly stated, along with a designated person in charge of it and a deadline for completion.[34]

CONCLUSION

Clinical trial success is largely dependent on the careful administration, observation, and auditing of study components. Protocol formulation, venue selection, participant recruiting and retention, data collecting and analysis, and regulatory compliance are just a few of the many tasks that make up effective trial management. keeping an eye on things like site visits, data evaluations, and pharmacovigilance aids in locating and resolving data inconsistencies, procedure violations, and possible safety issues. An extra degree of monitoring is provided by internal and external auditing, which confirms compliance with trial protocol, Good Clinical Practice (GCP) principles, and regulatory requirements.

The rigorous, multi-phase process of clinical drug development is necessary to guarantee the quality, safety, and efficacy of novel medications. Every phase, from the initial preclinical research to the post-marketing surveillance, is essential to reducing risks and optimizing therapeutic benefits. Innovations in digital health technologies, personalized medicine, and clinical trial design are increasing efficiency and success rates despite obstacles including high costs, long delays, and regulatory difficulties. Going forward, expediting medication development while upholding ethical and scientific integrity will require increased cooperation

between regulatory bodies, pharmaceutical corporations, and medical experts.

Clinical trials can guarantee the quality, integrity, and dependability of trial data, protect participant rights and welfare, and eventually aid in the creation of safe and effective clinical procedures by putting strong management, monitoring, and auditing procedures into place efficient therapies. Additionally, these procedures promote an environment of openness, responsibility, and ongoing development, which propels clinical research and innovative healthcare.

Clinical trials can successfully negotiate the challenges of clinical research, reduce risks, and accomplish their objectives by combining efficient management, monitoring, and auditing procedures. This will ultimately improve patient care and health outcomes. Clinical trials can have a significant influence on the healthcare industry and gain the trust of sponsors, investigators, regulatory bodies, and most importantly, participants, by maintaining the highest standards of quality, integrity, and compliance.

REFERENCES

1. Tamimi, N. A., & Ellis, P. (2009). Drug development: from concept to marketing!. *Nephron Clinical Practice*, *113*(3): c125-c131.
2. Steinmetz, K. L., & Spack, E. G. (2009). The basics of preclinical drug development for neurodegenerative disease indications. *BMC neurology*, *9*(Suppl 1): S2.
3. Zips, D., Thames, H. D., & Baumann, M. (2005). New anticancer agents: in vitro and in vivo evaluation. *in vivo*, *19*(1): 1-7.
4. Voskoglou-Nomikos, T., Pater, J. L., & Seymour, L. (2003). Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. *Clinical cancer research*, *9*(11): 4227- 4239.
5. Deore, A. B., Dhumane, J. R., Wagh, R., & Sonawane, R. (2019). The stages of drug discovery and development process. *Asian Journal of Pharmaceutical Research and Development*, *7*(6): 62-67.
6. Sedgwick, P. (2011). Phases of clinical trials. *Bmj*, *343*.
7. Manji, A., Brana, I., Amir, E., Tomlinson, G., Tannock, I. F., Bedard, P. L., ... & Razak, A. R. A. (2013). Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. *Journal of Clinical Oncology*, *31*(33): 4260-4267.
8. Ivy, S. P., Siu, L. L., Garrett-Mayer, E., & Rubinstein, L. (2010). Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. *Clinical Cancer Research*, *16*(6): 1726-1736.
9. Van Norman, G. A. (2019). Phase II trials in drug development and adaptive trial design. *JACC: Basic to Translational Science*, *4*(3): 428-437.
10. Berlin, J. A., Glasser, S. C., & Ellenberg, S. S. (2008). Adverse event detection in drug development: recommendations and obligations beyond phase 3. *American journal of public health*, *98*(8): 1366-1371.
11. Suvarna, V. (2010). Phase IV of drug development. *Perspectives in clinical research*, *1*(2): 57-60.
12. Fleming, T. R., & DeMets, D. L. (1993). Monitoring of clinical trials: issues and recommendations. *Controlled clinical trials*, *14*(3): 183-197.
13. Yao, B., Zhu, L., Jiang, Q., & Xia, H. A. (2013). Safety monitoring in clinical trials. *Pharmaceutics*, *5*(1): 94-106.
14. Sachs, G. S., Guille, C., & McMurrich, S. L. (2002). A clinical monitoring form for mood disorders. *Bipolar Disorders*, *4*(5): 323-327.
15. Trost, S. G., & O'Neil, M. (2014). Clinical use of objective measures of physical activity. *British journal of sports medicine*, *48*(3): 178-181.
16. Weijer, C., Shapiro, S., Fuks, A., Glass, K. C., & Skrutkowska, M. (1995). Monitoring clinical research: an obligation unfulfilled. *CMAJ: Canadian Medical Association Journal*, *152*(12): 1973.
17. Morse, M. A., Califf, R. M., & Sugarman, J. (2001). Monitoring and ensuring safety during clinical research. *Jama*, *285*(9): 1201-1205.
18. Amorim-Costa, C., Ayres-De-Campos, D., Sousa, P., & Bernardes, J. (2011). Audit of a fetal central monitoring station in a clinical setting. *The Journal of Maternal-Fetal & Neonatal Medicine*, *24*(10): 1249-1253.
19. Niu, J., Liu, J., Lee, T. C., Lin, Z. J., Mak, C., Tse, K. T., ... & Kwok, K. C. (2015). A new method to assess spatial variations of outdoor thermal comfort: Onsite monitoring results and implications for precinct planning. *Building and Environment*, *91*: 263-270.
20. Love, S. B., Yorke-Edwards, V., Ward, E., Haydock, R., Keen, K., Biggs, K., ... & Meakin, G. (2022). What is the purpose of clinical trial monitoring?. *Trials*, *23*(1): 836.
21. Simonova, M. V., Ilyukhina, L. A., Romantsev, G. M., Zeer, E. F., & Khamatnurov, F. T. (2016). Approaches to monitoring of competences and qualifications. *International Electronic Journal of Mathematics Education*, *11*(7): 2745-2760.
22. McDonald, C. J., Murray, R., Jeris, D., Bhargava, B., Seeger, J., & Blevins, L. (1977). A computer-based record and clinical monitoring system for ambulatory care. *American Journal of Public Health*, *67*(3): 240-245.
23. Molloy, S. F., & Henley, P. (2016). Monitoring clinical trials: a practical guide. *Tropical Medicine & International Health*, *21*(12): 1602-1611.
24. Farrell, B., Kenyon, S., & Shakur, H. (2010). Managing clinical trials. *Trials*, *11*: 1-6.
25. Morin, K., Rakatansky, H., Riddick Jr, F. A., Morse, L. J., O'Bannon III, J. M., Goldrich, M. S., ... &

Spillman, M. A. (2002). Managing conflicts of interest in the conduct of clinical trials. *Jama*, *287*(1): 78-84.
26. Bhatt, A. (2011). Quality of clinical trials: A moving target. *Perspectives in clinical research*, *2*(4): 124-128.
27. Mentz, R. J., Hernandez, A. F., Berdan, L. G., Rorick, T., O'Brien, E. C., Ibarra, J. C., ... & Peterson, E. D. (2016). Good clinical practice guidance and pragmatic clinical trials: balancing the best of both worlds. *Circulation*, *133*(9): 872-880.
28. Dickersin, K., & Rennie, D. (2003). Registering clinical trials. *Jama*, *290*(4): 516-523.
29. Kron, T., Haworth, A., & Williams, I. (2013, June). Dosimetry for audit and clinical trials: challenges and requirements. In *Journal of Physics: Conference Series* (Vol. 444, No. 1, p. 012014). IOP Publishing.
30. Goldacre, B., & Heneghan, C. (2014). Improving, and auditing, access to clinical trial results. *BMJ*, *348*.
31. Gnanalingham, J., Gnanalingham, M. G., & Gnanalingham, K. K. (2001). An audit of audits: are we completing the cycle?. *Journal of the Royal Society of Medicine*, *94*(6): 288-289.
32. Colquhoun, H. L., Brehaut, J. C., Sales, A., Ivers, N., Grimshaw, J., Michie, S., ... & Eva, K. W. (2013). A systematic review of the use of theory in randomized controlled trials of audit and feedback. *Implementation Science*, *8*: 1-8.
33. Redfern, S. J., & Norman, I. J. (1996). Clinical audit, related cycles and types of health care quality: a preliminary model. *International Journal for Quality in Health Care*, *8*(4): 331-340.